Biliary tract cancers (BTC) constitute epithelial malignancies of the biliary tree and include the following: Gallbladder cancer (GBC) and Cholangiocarcinoma (CCA). The CCA is further divided into intra-hepatic CCA, perihilar Klatskin’s tumour), and distal CCA. BTC constitutes approximately 3% of all gastrointestinal malignancies and is the most common hepatobiliary cancer after hepatocellular carcinoma.
Biliary tract cancer is usually diagnosed with the clinical examination of the abdomen, imaging scans using ultrasound, magnetic resonance imaging (MRI) or computed tomography (CT), and biopsy. Further investigations can help to determine the stage of cancer. Biliary tract cancer is staged according to tumour size, and the tumour commonly metastasizes via lymphatic spread to the regional lymph nodes, followed by hematogenous metastasis to the liver, lungs, and peritoneum. Also, patients usually develop distant metastasis in the late stages of the disease. The staging is used to decide the best treatment.
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market
The Biliary Tract Cancers (BTCs) market report also covers emerging drugs, current treatment practices, Biliary Tract Cancers (BTCs) market share of the individual therapies, current and forecasted Biliary Tract Cancers (BTCs) Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Biliary Tract Cancers (BTCs) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Biliary Tract Cancers (BTCs) Market Key Facts
As per DelveInsight estimates, total incident cases of Biliary Tract Cancers (BTCs) in the 7MM was assessed to be 70,111 in 2017, and are expected to increase during the study period.
Assessments as per DelveInsight estimates suggest that a higher number of Biliary Tract Cancers (BTCs) cases were found in the age group 70-79 years with 4,829 in 2017 in the US.
Among the European 5 countries, Germany had the highest incident population of Biliary Tract Cancers (BTCs) with 6,918 cases, followed by Italy, which had the incident population of 6,423 in 2017.
In 2017, the incident cases of Biliary Tract Cancers (BTCs) in Japan was found to be 28,907 which as per DelveInsight’s analysts, shall increase by 2030.
Key Benefits of Biliary Tract Cancers (BTCs) Market Report
-
Biliary Tract Cancers (BTCs) market report provides an in-depth analysis of Biliary Tract Cancers (BTCs) Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
-
The Biliary Tract Cancers (BTCs) market report will help in developing business strategies by understanding the Biliary Tract Cancers (BTCs) Market trends & developments, key players and future market competition that will shape and drive the Biliary Tract Cancers (BTCs) market in the upcoming years.
-
The Biliary Tract Cancers (BTCs) market report covers Biliary Tract Cancers (BTCs) current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Biliary Tract Cancers (BTCs) market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Biliary Tract Cancers (BTCs) Market
The market size of Biliary Tract Cancers (BTCs) is anticipated to increase during the study period, owing to the launch of various multiple-stage pipeline products in the market.
The Biliary Tract Cancers (BTCs) market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Biliary Tract Cancers (BTCs) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Biliary Tract Cancers (BTCs) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Biliary Tract Cancers (BTCs) Epidemiology
The Biliary Tract Cancers (BTCs) epidemiology section covers insights about historical and current Biliary Tract Cancers (BTCs) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Biliary Tract Cancers (BTCs) Drugs Uptake and Key Market Players
The Biliary Tract Cancers (BTCs) Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Biliary Tract Cancers (BTCs) market or expected to get launched in the market during the study period. The analysis covers Biliary Tract Cancers (BTCs) market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Some of the key companies in the Biliary Tract Cancers (BTCs) market includes:
Agios Pharmaceuticals
QED Therapeutics
Delcath Systems
Taiho Oncology
Merck Sharp & Dohme
Delcath Systems
AstraZeneca
Ipsen
BeiGene
Celgene
PCI Biotech
Eisai
Bristol-Myers Squibb
Bayer
Basilea Pharmaceutica
And others
Biliary Tract Cancers (BTCs) therapies covered:
Ivosidenib
Infigratinib
Melphalan Hydrochloride
Futibatinib
Bintrafusp Alfa
Melphalan Hydrochloride
Durvalumab
Nanoliposomal Irinotecan
Zanidatamab
Pembrolizumab
Nab-paclitaxel
Fimaporfin
Lenvatinib
Nivolumab
Regorafenib
Derazantinib
And many others
Table of Content
1. Key Insights
2. Executive Summary
3. Biliary Tract Cancers (BTCs) Competitive Intelligence Analysis
4. Biliary Tract Cancers (BTCs) Market Overview at a Glance
5. Biliary Tract Cancers (BTCs) Disease Background and Overview
6. Biliary Tract Cancers (BTCs) Patient Journey
7. Biliary Tract Cancers (BTCs) Epidemiology and Patient Population
8. Biliary Tract Cancers (BTCs) Treatment Algorithm, Current Treatment, and Medical Practices
9. Biliary Tract Cancers (BTCs) Unmet Needs
10. Key Endpoints of Biliary Tract Cancers (BTCs) Treatment
11. Biliary Tract Cancers (BTCs) Marketed Products
12. Biliary Tract Cancers (BTCs) Emerging Therapies
13. Biliary Tract Cancers (BTCs) Seven Major Market Analysis
14. Attribute Analysis
15. Biliary Tract Cancers (BTCs) Market Outlook (7 major markets)
16. Biliary Tract Cancers (BTCs) Access and Reimbursement Overview
17. KOL Views on the Biliary Tract Cancers (BTCs) Market.
18. Biliary Tract Cancers (BTCs) Market Drivers
19. Biliary Tract Cancers (BTCs) Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Related Reports
Biliary Tract Cancers (BTCs) Epidemiology Forecast
DelveInsight’s Biliary Tract Cancers (BTCs) – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Biliary Tract Cancers (BTCs) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Biliary Tract Cancers (BTCs) Pipeline Insights
Biliary Tract Cancers (BTCs) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Biliary Tract Cancers (BTCs) market.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd. 2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/